ArticleOncotarget2016

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.

Ryan E Henry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.